4F-MDMB-BINACA Stats & Data

Why add this: 4F‑MDMB‑BINACA belongs to a class of highly potent synthetic cannabinoids; EUDA reports emphasise that even low doses can cause severe poisoning and that products may be mis‑sold or adulterated. Therefore, precise measurement and conservative titration are essential. EUDA and case‑series on SCRA critical illness state there is no specific antidote; management is supportive with benzodiazepines for agitation/seizures and cardiorespiratory monitoring. EUDA also documents ‘hot‑spot’ risks from unevenly sprayed plant material or paper, and widespread SCRA adulteration of cannabis products and edibles; this justifies strong warnings against DIY spraying and against trusting appearance/branding. Polysubstance use is common and increases harms; combining CNS depressants (alcohol, opioids, benzodiazepines) elevates risk of coma/respiratory events, while stimulants add cardiovascular strain to a class already linked to tachycardia, hypertension, seizures and psychosis. Withdrawal and dependence are well‑documented for SCRAs and are often more severe than with cannabis, warranting the high addiction‑risk classification. Detectable urinary metabolites (e.g., 4‑OH‑MDMB‑BINACA; acid hydrolysis products) explain why impairment may persist beyond the peak even as parent levels fall. In emergencies: avoid redosing; seek help for chest pain, seizures, loss of consciousness, or uncontrollable agitation; naloxone will not reverse SCRA effects, but should still be given if opioid exposure is suspected (mixed supplies are increasingly documented). Prefer not to drive or operate machinery the same day; impairment can outlast the subjective high.